抗体受託製造市場：抗体タイプ、供給源、サービス、エンドユーザー別-2024-2030年の世界予測

抗体受託製造市場規模は2023年に163億4,000万米ドルと推計され、2024年には180億4,000万米ドルに達し、CAGR 10.82%で2030年には335億6,000万米ドルに達すると予測されています。

抗体受託製造には、抗体作製・精製工程の専門業者へのアウトソーシングが含まれます。このアプローチにより、バイオテクノロジー企業や製薬企業は、インフラへの多額の設備投資を必要とすることなく、モノクローナル抗体、ポリクローナル抗体、組換え抗体の生産において、外部の専門知識や高度な設備を活用することができます。抗体受託製造サービスは通常、細胞株開発、上流・下流工程、精製、最終製剤化など、幅広い工程をカバーしています。がん、自己免疫疾患、感染症などの慢性疾患の治療において抗体医薬が重視されるようになり、専門的な製造サービスの必要性が高まっています。革新的な抗体治療薬に対する規制当局の支援の増加は、生物製剤の合理化された承認と相まって、製造受託機関（CMO）との提携を促進しています。抗体受託製造に関連する品質リスクやコンプライアンスリスクの高まりに伴う知的財産権への懸念が、市場の成長を抑制しています。バイオプロセス、遺伝子工学、ハイスループットスクリーニングの技術進歩が新規抗体の開発を加速し、市場成長の機会を生み出しています。

抗体の種類均一性、特異性、大量生産能力からモノクローナル抗体のニーズが高まる

モノクローナル抗体は、特定の抗原を標的とする抗体の同一コピーです。単一のクローン細胞または細胞株によって産生され、同じエピトープにのみ結合する一価の親和性を持っています。受託製造では、モノクローナル抗体はハイブリドーマ開発、組換えDNA、ファージディスプレイなどの高度な技術によって作製されます。これらの抗体は、診断、治療（がん、自己免疫疾患、感染症などの疾患）、研究など幅広い用途に使用されています。その均一性、特異性、大量生産能力から、医学や生物学における貴重なツールとなっています。ポリクローナル抗体は、B細胞の異なるクローンによって産生される抗体分子の混合集団からなります。ポリクローナル抗体は単一の抗原上の複数のエピトープを認識し結合します。この多様性により、ポリクローナル抗体はしばしば免疫沈降法や免疫蛍光法において様々な抗原の検出に使用されます。製造には、ウサギ、ヤギ、マウスなどの適切な哺乳動物に抗原を免疫することが必要です。動物の免疫系は抗原に対する様々な抗体を産生し、血清から抗体を回収することができます。ポリクローナル抗体は、その高い感度とタンパク質を本来のコンフォメーションで捕らえる能力で高く評価されているが、バッチごとのばらつきは、その生産と使用において重要な考慮事項です。

エンドユーザー：抗体生産と精製における専門知識を活用するため、バイオテクノロジー企業や製薬企業で抗体受託製造の採用が増加しています。

学術・研究機関は、抗体受託製造市場におけるエンドユーザーの重要なセグメントを構成しています。多様な研究目的のために高度な抗体開発サービスを利用するこれらの機関は、疾病メカニズムの解明、新たな治療標的の発見、新規診断ツールの開発に注力しています。製造受託機関（CMO）との提携により、インフラに多額の投資をすることなく最先端の技術や専門知識を利用できるため、科学的発見やイノベーションのペースが加速されます。新興企業から老舗企業まで、バイオテクノロジー・製薬企業は、治療用抗体の開発、診断用試薬の製造など、さまざまな用途で抗体受託製造サービスに大きく依存しています。これらの企業は、特定の治療領域や新規のバイオテクノロジーアプローチに重点を置くことが多く、専門性が高く、スケーラブルでコスト効率の高い抗体製造ソリューションが必要となります。製造受託パートナーシップは、バイオテクノロジー企業が複雑な規制状況を乗り切り、バイオ医薬品製品開発サイクルに関連するリスクを管理し、イノベーションの市場投入までの時間を短縮することを可能にします。CMOとの提携により、製薬・バイオテクノロジー企業は抗体の生産・精製に関する専門知識を活用し、製造プロセスを最適化し、製品の品質と世界の規制基準への準拠を確保することができます。

地域別の洞察

南北アメリカは世界の市場情勢において非常に開拓が進んでいる地域です。この地域はバイオ医薬品の研究が盛んで、ヘルスケアへの支出も大きく、規制環境も整っています。米国には、早期開発から大規模生産まで幅広いサービスを提供する重要な医薬品製造受託機関（CMO）が複数存在します。カナダとブラジルもこの分野の成長を目の当たりにしているが、市場規模と技術進歩の点では米国がリードし続けています。アジア太平洋地域の抗体受託製造市場は、バイオテクノロジーへの投資の増加、バイオシミラーへの需要の高まり、ヘルスケアインフラの改善によって活性化しています。中国、韓国、インドなどの国々は、政府がバイオテクノロジーの進歩に有利な政策を実施しており、最先端を走っています。特に中国は、患者数が多く、バイオテクノロジー産業が成長していることから、CMOや開発・製造受託機関（CDMO）の設立が急増しています。この地域はコスト競争力のあるサービスを提供しており、品質基準の向上と相まって、抗体作製のアウトソーシング先として魅力的な場所となっています。EMEA（欧州・中東・アフリカ）地域は抗体受託製造市場において強い存在感を示しており、バイオ医薬品部門が高度に発展している欧州がリードしています。ドイツ、英国、スイスを含む国々は、既存プレーヤーと新興バイオテクノロジー企業の両方からなる洗練されたバイオテクノロジー・エコシステムで注目されています。厳しい規制基準が存在するため、高品質の製造プロセスと生産物が保証されています。中東とアフリカは、ヘルスケア・インフラへの投資とバイオテクノロジー研究への関心の高まりにより、徐々に追いついてきています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗体受託製造市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗体受託製造市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.抗体受託製造市場の市場規模および予測は？

2.抗体受託製造市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.抗体受託製造市場の技術動向と規制枠組みは？

4.抗体受託製造市場における主要ベンダーの市場シェアは？

5.抗体受託製造市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • バイオ医薬品治療薬の開発と商業化の必要性
    • 慢性疾患の治療のための高度な抗体の需要の高まり
    • パーソナライズされた医薬品への関心の高まり
  • 抑制要因
    • 生物製剤の開発と製造に関する懸念
  • 機会
    • バイオ医薬品パイプラインの増加と受託製造サービスの拡大
    • 抗体生産のための研究開発予算を世界規模で増加
  • 課題
    • 二重/多重特異性抗体フォーマットの複雑さ
• 市場セグメンテーション分析
  • 抗体の種類：均一性、特異性、大規模生産能力によりモノクローナル抗体の需要が高まっています。
  • エンドユーザー：抗体の生産と精製に関する専門知識を活用するため、バイオテクノロジー企業と製薬企業の間で抗体受託製造の採用が増加しています。
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 抗体受託製造市場抗体の種類別

• モノクローナル抗体
• ポリクローナル抗体

第7章 抗体受託製造市場：ソース別

• 哺乳類
• 微生物

第8章 抗体受託製造市場：サービス別

• 分析開発と品質管理
• 細胞株の開発
• プロセス開発

第9章 抗体受託製造市場：エンドユーザー別

• 学術機関および調査機関
• バイオテクノロジーおよび製薬企業

第10章 南北アメリカの抗体受託製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の抗体受託製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの抗体受託製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • サムスンバイオロジクスとレゴケムバイオサイエンスが固形腫瘍治療のためのADCイノベーションを加速するために戦略的提携を締結
  • アラゲン、バイオ医薬品製造能力強化のためバンガロール施設に3,000万米ドルを投資
  • KBI Biopharma、加速製造ソリューションを備えたモノクローナル抗体開発のSUREmAbを発表
• 戦略分析と提言

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ANTIBODIES CONTRACT MANUFACTURING MARKET DYNAMICS
• FIGURE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT & QUALITY CONTROL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT & QUALITY CONTROL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICALS COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICALS COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 45. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 46. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 47. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 48. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 49. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 50. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 51. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 52. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 53. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 54. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 55. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 56. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 57. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 58. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 59. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 60. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 61. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 62. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 63. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 64. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 65. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 66. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 67. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 68. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 69. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 70. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 71. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 72. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 73. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 74. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 75. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 76. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 77. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 78. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 79. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 80. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 81. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 82. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 83. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 84. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 86. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 88. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 90. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 92. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 94. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 95. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 96. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 97. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 98. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 99. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 100. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 101. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 102. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 103. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 104. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 105. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 106. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 107. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 108. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 109. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 110. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 111. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 112. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 113. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 114. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 115. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 116. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 117. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 120. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 121. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 122. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 123. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 124. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 125. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 126. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 127. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 128. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 129. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 130. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 131. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 132. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 133. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 134. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 135. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 136. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 137. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 138. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 139. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 140. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 141. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 144. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 145. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 146. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 147. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 148. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 149. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 150. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 151. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 152. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 153. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 154. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 155. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 156. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 157. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 158. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 159. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 160. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 161. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 162. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 164. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 168. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 169. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 170. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 171. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 172. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 173. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 174. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 175. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 176. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 177. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 178. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 179. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 180. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 181. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 182. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 183. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 184. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 185. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 186. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 187. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 188. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 189. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 190. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 201. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 202. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 203. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 204. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 205. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 206. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 207. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 208. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 209. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 210. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 211. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 212. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 213. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 214. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 215. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 216. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 217. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 218. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 219. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 220. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 221. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 222. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 223. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 224. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 225. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 226. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 227. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 228. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 229. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 230. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 231. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 232. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 233. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 234. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 235. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 236. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 237. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 238. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 239. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 240. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 241. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 242. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 243. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 244. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 245. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 246. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 247. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 248. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 249. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 250. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 251. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 252. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 253. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 254. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 255. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 256. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 257. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 258. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 259. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 260. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 261. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 262. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 263. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 264. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 265. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 266. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 267. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 268. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 269. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 270. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 271. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 272. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 273. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 274. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 275. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 276. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 277. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 278. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 279. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 280. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 281. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 282. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 283. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 284. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 285. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 286. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 287. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 288. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 289. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 290. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 291. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 292. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 293. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 294. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 295. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 296. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 297. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 298. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 299. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 300. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 301. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 302. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 303. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 304. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 305. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
• TABLE 306. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
• TABLE 307. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 308. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 310. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA ANTI

[198 Pages Report] The Antibodies Contract Manufacturing Market size was estimated at USD 16.34 billion in 2023 and expected to reach USD 18.04 billion in 2024, at a CAGR 10.82% to reach USD 33.56 billion by 2030.

Antibodies contract manufacturing includes the outsourcing of antibody production and purification processes to specialized service providers. This approach allows biotechnology and pharmaceutical companies to leverage external expertise and advanced facilities for the production of monoclonal, polyclonal, and recombinant antibodies without the need for significant capital investments in infrastructure. Antibodies contract manufacturing services typically cover a broad spectrum of processes, including cell line development, upstream and downstream processing, purification, and final formulation. The growing emphasis on antibody-based drugs in the treatment of chronic diseases such as cancer, autoimmune diseases, and infectious diseases significantly fuels the need for specialized manufacturing services. Increasing regulatory support for innovative therapeutic antibodies, combined with streamlined approvals for biologics, promotes partnerships with contract manufacturing organizations (CMOs). Intellectual property concerns with rising quality and compliance risks associated with antibody contract manufacturing is restraining the growth of the market. Technological progress in bioprocessing, genetic engineering, and high-throughput screening accelerates the development of novel antibodies, creating opportunities for market growth.

Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities

Monoclonal antibodies are identical copies of an antibody that targets a specific antigen. They are produced by a single clone of cells or cell lines and have monovalent affinity, binding only to the same epitope. In the context of contract manufacturing, monoclonal antibodies are generated through sophisticated technologies such as hybridoma development, recombinant DNA, or phage display. These antibodies have a broad range of applications in diagnostics, therapeutics (for diseases such as cancer, autoimmune diseases, and infectious diseases), and research. Their uniformity, specificity, and large-scale production capabilities make them invaluable tools in medicine and biology. Polyclonal antibodies consist of a mixed population of antibody molecules that are produced by different clones of B cells. They recognize and bind to multiple epitopes on a single antigen. Due to this diversity, polyclonal antibodies are often used for detecting a wide range of antigens in immunoprecipitation and immunofluorescence assays. Production involves the immunization of a suitable mammal, such as a rabbit, goat, or mouse, with an antigen. The animal's immune system produces a wide array of antibodies against the antigen, which can then be collected from the serum. Polyclonal antibodies are appreciated for their high sensitivity and ability to capture proteins in their native conformation, but variability from batch to batch is a significant consideration in their production and use.

End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification

Academics & research institutions constitute a significant segment of the end-users in the antibodies contract manufacturing market. Utilizing advanced antibody development services for diverse research purposes, these entities focus on understanding disease mechanisms, discovering new therapeutic targets, and developing novel diagnostics tools. The partnership with contract manufacturing organizations (CMOs) allows them to access cutting-edge technologies and expertise without the need for substantial investments in infrastructure, thereby accelerating the pace of scientific discoveries and innovations. Biotechnology & pharmaceutical companies, ranging from startups to well-established firms, heavily rely on antibody contract manufacturing services for various applications, including therapeutic antibody development, diagnostic reagent production, and more. These companies often focus on specific therapeutic areas or novel biotechnological approaches, necessitating the need for specialized, scalable, and cost-effective antibody production solutions. Contract manufacturing partnerships enable biotech companies to navigate the complex regulatory landscapes and manage the risks associated with the biopharmaceutical product development cycle, facilitating a quicker time-to-market for their innovations. The collaboration with CMOs allows pharmaceutical & biotechnology firms to leverage specialized expertise in antibody production and purification, optimize manufacturing processes, and ensure product quality and compliance with global regulatory standards, thus supporting their efforts to deliver safe and effective treatments to patients worldwide.

Regional Insights

The Americas represents a highly developing landscape for the global antibodies contract manufacturing market attributed to the region's robust biopharmaceutical research landscape, significant healthcare spending, and supportive regulatory environment. The US houses several significant contract manufacturing organizations (CMOs) that offer a wide range of services, from early-stage development to large-scale production. Canada and Brazil are also witnessing growth in this sector, though the US continues to lead in terms of market size and technological advancements. The antibody contract manufacturing market in Asia-Pacific is fueled by increasing investment in biotechnology, rising demand for biosimilars, and improving healthcare infrastructure. Countries such as China, South Korea, and India are at the forefront, with their governments implementing favorable policies for biotech advancements. China, in particular, has seen a surge in the establishment of CMOs and contract development and manufacturing organizations (CDMOs) owing to its large patient population and growing biotech industry. The region offers cost-competitive services, which, combined with improving quality standards, makes it an attractive location for outsourcing antibody production. The EMEA region exhibits a strong presence in the antibodies contract manufacturing market, with Europe leading the way due to its highly developed biopharmaceutical sector. Countries including Germany, the United Kingdom, and Switzerland are notable for their sophisticated biotech ecosystems, comprising both established players and emerging biotechs. The presence of stringent regulatory standards ensures high-quality manufacturing processes and outputs. The Middle East and Africa are gradually catching up, with investments in healthcare infrastructure and an increasing focus on biotechnology research.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibodies Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibodies Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibodies Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abeomics, Absolute Antibody by LSBio, Advanced ChemTech, Inc., AGC Biologics, Antibodies, Inc., AstraZeneca, Boehringer Ingelheim Biopharmaceuticals GmbH., Bryllan LLC, Catalent, Inc., CD BioSciences, Charles River Laboratories International, Inc., Eli Lilly and Company, FUJIFILM Holdings Corporation, Fujirebio Inc. by H.U. Group Holdings, Inc., Hycult Biotechnology (H.B.T.) B.V., Labcorp Drug Development, Lonza Group Ltd., Merck KGaA, Molecular Depot LLC, Pierre Fabre S.A, Samsung Biologics, Sapphire Bioscience Pty. Ltd., Scantibodies Laboratory, Inc., Synthon International Holding B.V., The Serum Institute of India, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibodies Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Antibody Type
  • Monoclonal Antibodies
  • Polyclonal Antibodies

• Source
  • Mammalian
  • Microbial

• Services
  • Analytical Development & Quality Control
  • Cell Line Development
  • Process Development

• End-User
  • Academics & Research Institutions
  • Biotechnology & Pharmaceuticals Companies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibodies Contract Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibodies Contract Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Antibodies Contract Manufacturing Market?

4. What is the market share of the leading vendors in the Antibodies Contract Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Antibodies Contract Manufacturing Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Development and commercialization need for biopharmaceutical therapeutics
    • 5.1.1.2. Surging need for advanced antibodies for the treatment of chronic diseases
    • 5.1.1.3. Rising preference for personalized medicines
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns regarding development and manufacturing of biologics
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing number of biologics pipelines and growing contract manufacturing service
    • 5.1.3.2. Increasing the R&D budget for the production of antibodies globally
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity of bi/multispecific antibody formats
• 5.2. Market Segmentation Analysis
  • 5.2.1. Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities
  • 5.2.2. End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Antibodies Contract Manufacturing Market, by Antibody Type

• 6.1. Introduction
• 6.2. Monoclonal Antibodies
• 6.3. Polyclonal Antibodies

7. Antibodies Contract Manufacturing Market, by Source

• 7.1. Introduction
• 7.2. Mammalian
• 7.3. Microbial

8. Antibodies Contract Manufacturing Market, by Services

• 8.1. Introduction
• 8.2. Analytical Development & Quality Control
• 8.3. Cell Line Development
• 8.4. Process Development

9. Antibodies Contract Manufacturing Market, by End-User

• 9.1. Introduction
• 9.2. Academics & Research Institutions
• 9.3. Biotechnology & Pharmaceuticals Companies

10. Americas Antibodies Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Antibodies Contract Manufacturing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Antibodies Contract Manufacturing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Samsung Biologics and LegoChem Biosciences Forge Strategic Alliance to Accelerate ADC Innovation for Solid Tumor Treatment
  • 13.3.2. Aragen Invests USD 30 Million in Bangalore Facility to Boost Biologics Manufacturing Capabilities
  • 13.3.3. KBI Biopharma Unveils SUREmAb, Monoclonal Antibody Development with Accelerated Manufacturing Solutions
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio